ArticleEmerging microbes & infections2024
Evolutionary accumulation of
Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Micafungin microevolution inVirulence · 2026Article
- FKS1/2-variant independent mechanisms underlying the emergence of resistance in echinocandin-refractory Candida auris infections.Nature communications · 2026Article
- Segmental duplications and supernumerary chromosomes drive antifungal drug resistance in Candida auris.Nature communications · 2026Article
- Micafungin exposure drives multidrug resistance inbioRxiv : the preprint server for biology · 2026Article
- Clinical characteristics, healthcare-associated exposures, and antifungal susceptibility patterns of Candida auris colonization and invasive infections: a retrospective observational study at a single center in Turkey.BMC infectious diseases · 2026Observational
- Article
- Deciphering the multidrug resistance paradigm inAntimicrobial agents and chemotherapy · 2026Review
- UnderstandingJournal of medical microbiology · 2026Review
- Article
- In Vivo Evolution of Candida auris Multidrug Resistance in a Patient Receiving Antifungal Treatment.The Journal of infectious diseases · 2025Article
- Pathogen virulence genes: Advances, challenges and future directions in infectious disease research (Review).International journal of molecular medicine · 2025Review
- A Candidozyma (Candida) auris-Optimized Episomal Plasmid-Induced Cas9-Editing System Reveals the Direct Impact of the S639F-Encoding FKS1 Mutation.The Journal of infectious diseases · 2025Article
- Osh2 mediatesAntimicrobial agents and chemotherapy · 2025Article
- Candida auris is emerging as a prevalent urinary pathogen.PLoS pathogens · 2025Article
- RapidmSphere · 2025Article
- The multidrug-resistantCurrent research in microbial sciences · 2025Review
- First report of bloodstream infection caused byFrontiers in cellular and infection microbiology · 2025Article
- The rising challenge ofFrontiers in microbiology · 2025Review
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- Unveiling the hidden risk of caspofungin: insights from three adverse event reporting systems and network pharmacology integration.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDrug resistance to echinocandins, first-line drugs used to treat
findingsSix echinocandin minimum inhibitory concentration (MIC)-elevated
interpretationEchinocandin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.